CTIS2024-516438-36-00进行中（未招募）1 期
A phase II, open-label, single arm study to evaluate the efficacy of Luspatercept in Erythropoiesis-stimulatingagent naive lower-risk MDS patients with or without ring sideroblasts who do not require RBC transfusions (LENNON) - LENNO
niversitaet Leipzig0 个研究点目标入组 30 人开始时间: 2024年8月5日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Diagnosis of MDS according to WHO classification, Very low-, low-, or intermediate-risk disease with up to 3.5 score points according to revised International Prognostic Scoring System (IPSS-R) classification, Non-transfusion dependence (NTD) according to IWG 2018, Symptomatic anemia: mean baseline Hb < 10 g/d
排除标准
- •Secondary MDS, Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or gastrointestinal bleeding, Prior allogeneic or autologous stem cell transplant, ECOG > 2, Prior ESA treatment
研究者
相似试验
招募中
1 期
A global study of midostaurin in combination with chemotherapy to evaluate safety, efficacy, and pharmacokinetics in newly diagnosed pediatric patients with FLT3-mutated AMuntreated FLT3-mutated Acute Myeloid LeukemiaMedDRA version: 21.0Level: LLTClassification code: 10000886Term: Acute myeloid leukemia Class: 10029104CTIS2023-509834-20-00ovartis Pharma AG29
招募中
不适用
The study to evaluate the safety, efficacy, and pharmacokinetics of twice daily midostaurin (PKC412) combined with standard chemotherapy and as a single agent post-consolidation therapy in children with untreated FLT3-mutated AMDiseases of the blood and blood -forming organs and certain disorders involving the immune mechanismKCT0004051ovartis Korea4
进行中（未招募）
1 期
A Phase II, open-label, single arm study to evaluate the safety, efficacy, and pharmacokinetics of twice daily midostaurin (PKC412) combined with standard chemotherapy and as a single agent post-consolidation therapy in children with untreated FLT3-mutated AMuntreated FLT3-mutated acute myeloid leukemiaMedDRA version: 21.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864EUCTR2017-004830-28-DEovartis Pharma AG23
进行中（未招募）
1 期
A Phase II, open-label, single arm study to evaluate the safety, efficacy, and pharmacokinetics of twice daily midostaurin (PKC412) combined with standard chemotherapy and as a single agent post-consolidation therapy in children with untreated FLT3-mutated AMuntreated FLT3-mutated acute myeloid leukemiaMedDRA version: 21.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-004830-28-ATovartis Pharma AG23
进行中（未招募）
1 期
A Phase II, open-label, single arm study to evaluate the safety, efficacy, and pharmacokinetics of twice daily midostaurin (PKC412) combined with standard chemotherapy and as a single agent post-consolidation therapy in children with untreated FLT3-mutated AMEUCTR2017-004830-28-ITOVARTIS PHARMA AG52